HENDERSON, Nev., Oct. 9, 2024
/PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)
("Volition"), a multi-national epigenetics company, is taking part
in a webinar hosted by Edison Group, to expound new data, presented
at ESICM LIVES 2024, the annual congress of the European Society of
Intensive Care Medicine, earlier this week.
Given the extensive size and scope of the three independent
studies on the potential use of Nu.Q® NETs in sepsis management,
which included over 3000 patients and more than 14,000 patient
samples, the webinar aims to provide stakeholders with a
comprehensive understanding of the data and offer insights into how
Volition's nucleosome quantification technology could be used
in clinical practice.
The webinar takes place on Monday, October 21, at
10:00 AM U.S. Eastern Time and will
include updates from Volition's Dr. Andrew
Retter (Chief Medical Officer) and Mr. Gael Forterre (Chief
Commercial Officer).
Dr. Andrew Retter said:
"During our upcoming webinar, we will undertake a deep dive into
the data presented at ESICM 2024, highlighting research
findings from large independent studies on the potential use of our
Nu.Q® NETs H3.1 assay to enhance sepsis management in clinical
practice.
"We will explore the role of the role of H3.1 nucleosomes in
NETosis; why elevated levels of H3.1 are a cause for concern in
sepsis patients and examine how the Nu.Q® NETs biomarker has
the potential to predict organ failure."
Gael Forterre, Volition's Chief Commercial Officer, added:
"The findings from these latest Nu.Q® NETs studies are vital to
our commercialization efforts and will support our ongoing
licensing discussions with key industry players."
Nu.Q® NETs, Volition's nucleosome quantification technology, is
a simple, low-cost, accessible test that quantifies an individual's
level of circulating H3.1 nucleosomes in the bloodstream, a
surrogate marker for Neutrophil Extracellular Traps (NETs).
Although NETs play a critical role in our normal immune response,
elevated levels of NETs can lead to tissue damage, and in severe
cases, sepsis, organ failure and death.
The Nu.Q® NETs panel and Q&A event is being hosted by
Soo Romanoff (Managing Director,
Healthcare) at Edison Group.
Event Details:
Title: Volition Nu.Q® NETs Data Insights Webinar
Date: Monday October 21,
2024
Time: 10:00 AM U.S
Eastern
Register at: Edison Registration
To register for Volition's Data Insights webinar click
here. The event will be recorded and available afterward on
demand.
Volition is developing simple, easy-to-use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases including cancer in both humans and animals. For more
information about Volition's technology go to:
www.volition.com.
About Volition
Volition is a multi-national company focused on advancing the
science of epigenetics. Volition is dedicated to saving lives and
improving outcomes for people and animals with life-altering
diseases through earlier detection, as well as disease and
treatment monitoring.
Through its subsidiaries, Volition is developing and
commercializing simple, easy to use, cost-effective blood tests to
help diagnose and monitor a range of diseases, including some
cancers and diseases associated with NETosis, such as sepsis. Early
diagnosis and monitoring have the potential not only to prolong the
life of patients, but also improve their quality of life. For more
information about Volition's technology go to:
www.volition.com.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. Such website address is included
in this document as an inactive textual reference only.
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, the potential uses, benefits and
effectiveness of Volition's Nu.Q® technology platform. Volition's
actual results may differ materially from those indicated in these
forward-looking statements due to numerous risks and uncertainties,
including, without limitation, results of studies testing the
efficacy of its tests. For instance, if Volition fails to develop
and commercialize diagnostic, prognostic or disease monitoring
products, it may be unable to execute its plan of operations. Other
risks and uncertainties include Volition's failure to obtain
necessary regulatory clearances or approvals to distribute and
market future products; a failure by the marketplace to accept the
products in Volition's development pipeline or any other
diagnostic, prognostic or disease monitoring products Volition
might develop; Volition's failure to secure adequate intellectual
property protection; Volition will face fierce competition and
Volition's intended products may become obsolete due to the highly
competitive nature of the diagnostics and disease monitoring market
and its rapid technological change; downturns in domestic and
foreign economies; and other risks, including those identified in
Volition's most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as other documents that Volition
files with the Securities and Exchange Commission. These statements
are based on current expectations, estimates and projections about
Volition's business based, in part, on assumptions made by
management. These statements are not guarantees of future
performance and involve risks, uncertainties and assumptions that
are difficult to predict. Forward-looking statements are made as of
the date of this press release, and, except as required by law,
Volition does not undertake an obligation to update its
forward-looking statements to reflect future events or
circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos
are trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
Video: https://www.youtube.com/watch?v=ZX-d95V8UfQ
Media Enquiries:
Louise
Batchelor/Debra Daglish
Volition
mediarelations@volition.com
+44 (0)7557 774620
View original content to download
multimedia:https://www.prnewswire.com/news-releases/volition-to-share-new-nets-in-sepsis-management-data-insights-at-upcoming-webinar-302271463.html
SOURCE VolitionRx Limited